Cardiff Oncology (CRDF) Stock Forecast & Price Target

Cardiff Oncology is viewed positively because the settlement with Nerviano removes a major legal overhang and secures clearer global rights around onvansertib, its lead PLK1 inhibitor, which supports development continuity and strategic optionality. The amended agreement also strengthens exclusivity, adds structured governance, and preserves Cardiff’s ability to advance a planned Phase 3 program while resolving all outstanding claims in the U.S. District Court for the Southern District of California. Fundamentally, the company’s outlook is reinforced by onvansertib’s focus on RAS-mutated metastatic colorectal cancer, a large underserved population, and by early clinical signals across other PLK1-driven cancers, which together support the drug’s commercial and clinical potential.

Cardiff Oncology is facing a weak fundamental setup because its lead asset, onvansertib, still carries only a 25% probability of launch in 1L KRAS/NRAS+ mCRC, while value is highly dependent on an unproven Phase 2 program and a single clinical and regulatory path. The outlook is further pressured by legal overhang after Nerviano terminated the license agreement on May 27, 2026, alleging material breach and threatening control of development and regulatory activities, which creates execution and ownership uncertainty around the core asset. With estimated firm value only $848M, 11% discount rate, and explicit risks of negative CRDF-004 data, delays, approval failure, competition, and dilution, the stock’s downside appears driven by binary trial risk and worsening contractual leverage.